Indeed, the cytokine profile of ARDS would normally be seen as a desirable immune response against tumours.12 Although rare, cases of CRS have been reported following anti-PD-1 monotherapy, though are more typical with chimaeric antigen receptor (CAR) T-cell therapies. This evidence concerns the gene PDCD1 and neoplasm.